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Faisal, Fazle Elahi. M.Sc. The University of Memphis. 12/2011. Computing 
Network of Diseases and Pharmacological Entities through the Integration of Distributed 
Literature Mining and Ontology Mapping. Major Professor: Dr. Mohammed Yeasin. 
The proliferation of “–omics” (such as, Genomics, Proteomics) and “–ology” 
(such as, System Biology, Cell Biology, Pharmacology) have spawned new frontiers of 
research in drug discovery and personalized medicine. A vast amount (21 million) of 
published research results are archived in the PubMed and are continually growing in 
size. To improve the accessibility and utility of such a large number of literatures, it is 
critical to develop a suit of semantic sensitive technology that is capable of discovering 
knowledge and can also infer possible new relationships based on statistical co-
occurrences of meaningful terms or concepts. In this context, this thesis presents a unified 
framework to mine a large number of literatures through the integration of latent 
semantic analysis (LSA) and ontology mapping. In particular, a parameter optimized, 
robust, scalable, and distributed LSA (DiLSA) technique was designed and implemented 
on a carefully selected 7.4 million PubMed records related to Pharmacology. The DiLSA 
model was integrated with MeSH to make the model effective and efficient for a specific 
domain. An optimized multi-gram dictionary was customized by mapping the MeSH to 
build the DiLSA model. A fully integrated web-based application, called PharmNet, was 
developed to bridge the gap between biological knowledge and clinical practices. 
Preliminary analysis using the PharmNet shows an improved performance over global 
LSA model. A limited expert evaluation was performed to validate the retrieved results 
and network with biological literatures. A thorough performance evaluation and 
validation of results is in progress. 
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Pharmacology is the study of exploring the interactions between drugs or 
chemicals and organisms. The large volume of articles related to pharmacology 
constitutes the importance of biological literature mining. However, there are lots of 
challenges in the mining, such as computational complexity, scalability, systemic bias 
etc. This chapter outlines the motivation, contribution, related works and brief summary 
of this study.  
1.1 Motivation 
Pharmacology mainly deals with the interactions between drugs or chemicals and 
organisms. In particular, it explores the effect of drugs on cellular components and 
biological functions in an organism. There are two main areas in this study: 
pharmacodynamics and pharmacokinetics. Pharmacodynamics is the study of effects of 
drugs on biological functions in an organism. And, pharmacokinetics is the study of 
effects of biological functions on drugs.  
Personalize medicine [1] is now a hot topic, not only for the vision of proper 
health care, but also for the availability and affordability of genome sequencing 
technology. People will be able to get the full genome sequencing at about $1000 very 
soon [2]. The main challenge in personalized medicine lies in transforming genetic 
information, along with its interaction with drugs and biological functions into clinical 
practice. A rigorous analysis between pharmacological entities, including disease, 
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diagnosis, drug, cellular compounds and other factors (such as environment) is essential 
to bridge the gap between genetic sequencing and medication.  
Information processing in pharmacology is one of the important factors for the 
achievement of personalized medicine, as it deals with the influence of drug response in 
patients. However, most of the biological knowledge is preserved as published contents, 
unlike many other sciences which maintain the knowledge in the form of formula or 
equation. Furthermore, the number of journals, articles, books, etc. in biology is huge. 
For instance, PubMed consists of more than 21 million publication abstracts and 
references on life science, medical science and other related topics. As this massive 
literature is mostly unstructured, it is of great interest to extract relationships between 
pharmacological entities automatically using natural language processing techniques. We 
get several benefits out of this processing. Firstly, this process extracts known 
relationships between interesting pharmacological entities in a structured manner. 
Secondly, natural language processing can extract potential unknown associations. It 
assists pharmacological researchers to design a new hypothesis.  
Biological literature mining provides different types of benefits to advance 
pharmacology research. Firstly, literature mining helps to organize unstructured text 
information in a structured way. It is useful to extract useful information for a certain 
purpose. For instance, a researcher can easily extract relationship between a gene and a 
drug from structured text.  
Secondly, literature mining helps to find the concise information. For instance, the 
relationship between gene and drug can be represented in network format, which 
provides better visualization.  
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Thirdly, literature mining can display necessary publications a researcher is 
interested in. It is important for a researcher to go through the relevant existing 
publication to establish and experiment on a new hypothesis. In this case, mining 
technique survives the researchers from succumbing in the sea of publications and helps 





Figure 1.1. Identification of potential association from biological network. A potential 
indirect association between a drug (here, Drug2) and a disease (here, Disease2) is 




Fourthly, literature mining can assist researchers to generate a new hypothesis by 
providing them potential experimental conditions. This functionality is also known as 
knowledge discovery. For instance, a literature mining framework may be able to infer a 
potential unknown relationship between a gene and a drug form known relationships. In 
latent semantic analysis, it is done by second order co-occurrence. Figure 1.1 illustrates a 
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graphical view of identification of potential association between pharmacological entities 
through network representation. Such assistive tools may help researchers to prove or 
disprove a new hypothesis focusing on a small set of experimental conditions. Finally, 
literature mining can eliminate a huge amount of redundant and unnecessary information 
from biological text data.  
There are lots of issues yet to be resolved in biological literature mining. In brief, 
the challenges lie in scalability, systemic bias, identification of entities, parameter 
optimization, network visualization, preserving biological meaning, and translation of 
discoveries into clinical practice. These issues are really important, as we want to provide 
the researchers with best information extraction. 
 Scalability: With the rapidly growing size of biological text data, scalability of a 
literature mining framework is a major concern. Processing of large volume and 
high dimensional text data is becoming computationally infeasible. Furthermore, 
continuous inclusion of new biological literature creates a challenge to merge new 
information into system with efficient computation. 
 Systemic bias: Structure of biological literature data creates a systemic bias in a 
data mining model. A biological entity having large volume of literature tends to 
provide weaker correlation against a query, increasing the false negative rate of 
the model. Furthermore, an entity having small amount of literature tends to show 
strong association against a query, increasing the false positive rate. Elimination 




 Identification of entities: In a biological literature mining framework, mining is 
performed on a set of biological entities such as gene, protein, disease, drug, 
diagnosis, cellular components, chemical compounds etc. In case of 
pharmacological literature mining, we are mostly interested in chemical 
compounds, cellular compounds, diagnosis, procedures etc. However, there are a 
lot of redundant and less informative pharmacological entities, which adds noise 
to the model. Hence, identification of proper entities is an important issue.  
 Parameter optimization: There are important parameters in a literature mining 
framework, including corpus, dictionary, type of model, dimensionality, similarity 
measure etc. To ensure the quality of the model, it is important to choose the 
parameters in an optimized way. 
 Network visualization: One of the main objectives of a biological literature 
mining frameworks is to visualize the interaction between the biological entities. 
Already there are web based network visualization tools, which can visualize the 
direct relationships between biological entities. However, there are some entities 
which do not have direct relationships between them but they have strong 
association between them through some other biological entities. It has been a big 
challenge to identify these entities which can reveal a non-established biological 
relationship and provide visualization as a network. Figure 1.2 illustrates a 
pharmacological network visualization connecting pharmacological entities: 








Figure 1.2: Pharmacological network visualization. The network is constructed by the 
visualization of the relationships between pharmacological entities: disease, drug, 




 Biological meaning preservation: Biological literature mining is different from 
literature mining in other domains in the sense that it requires to preserve the 
biological meaning. If special care is not taken regarding this issue, the original 
biological meaning may be lost. For instance, vector space model treats each term 
in a corpus separately. Hence, the multi-gram meaning is lost. It is a big challenge 
to maintain the originality of the biological meaning. 
 Translation of discoveries into clinical practice: The discovered knowledge 
from a literature mining framework is worthless unless it is translated into clinical 
practice. However, only literature mining is not sufficient for this purpose. In 
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particular, it requires the integration of discovered knowledge from literature, 
genome analysis, genotype-phenotype correspondence etc. It constitutes a major 
challenge how to integrate all available information to translate them into medical 
application. 
The scalability, systemic bias, identification of entities, parameter optimization, 
network visualization and biological meaning preservation creates the motivation of this 
thesis. Furthermore, we brought some outlines which bridge between knowledge 
discovery and clinical application. 
1.2 Contribution of the Thesis 
The goal of this study is to design and implement a framework to facilitate 
literature mining to explore relationship between pharmacological entities such as cellular 
components, chemical compounds, biological factors, disease, diagnosis, procedures etc. 
We addressed the following research issues to ensure the scalability and quality of 
information retrieval of the model. 
 Distributed literature mining: We designed and implemented a distributed 
literature mining framework for this study. We showed how to take advantage 
over biological literature data to achieve a distributed model.  Our proposed 
model addresses the scalability and systemic bias issue. Hence, we achieved 
computational efficiency and quality information retrieval. Our result shows how 
distributed model can eliminate or reduce the systemic bias effect.  
 Multi-gram model: We used multi-gram model to make sure that the biological 
meaning of a multi-gram word is not lost. We know that vector space model treats 
each word independently and therefore, lose the meaning of multi-gram words. 
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For instance, if we treat the two words Blood and Cancer separately, then the 
meaning of Blood Cancer is lost. However, we incorporated multi-gram facility in 
a vector space model. Our result shows how multi-gram model can achieve better 
information retrieval against one-gram model. 
 Parameter optimization: As we used latent semantic analysis for the purpose of 
literature mining, we needed to choose proper parameters to ensure the quality of 
information retrieval. The model parameters include corpus, dictionary, TF-IDF 
method, dimensionality and similarity measure. We explored different parameters 
for our experiment and chose the best parameters ensuring maximum quality 
information retrieval. 
 Identification of entities: We performed statistical analysis to identify the 
pharmacological entities to perform literature mining. We showed how to choose 
informative and non-redundant entities by using their corpus properties. In 
addition, we introduced as heuristic based specificity function to identify useful 
pharmacological entities. 
 Network visualization: We developed a web analysis tool called PharmNet to 
explore the relationship between biological entities graphically. Instead of 
drawing the network only using the user query, PharmNet also includes the 
related pharmacological entities to draw the network. Hence, PharmNet can 
discover categorical similarity between biological queries. In other words, 
PharmNet shows the pharmacological entities connecting two or more biological 
queries. PharmNet is hosted at http://141.225.166.104:8080/pharma.  
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1.3 Related Works 
Due to the nature of biological literature, it has been a great interest to perform 
literature mining to find the relationship among biological components. Natural language 
processing and machine learning techniques have been applied on biological text to 
transform unstructured text into computational form to understand the functional 
concepts of biological compounds. However, PubMed [3] is a literature database, which 
comprises of about 21 million publications in life science or related topics from 
MEDLINE maintained by National Technology for Biotechnology Information (NCBI). 
These articles are annotated with Medical Subject Heading (MeSH) [4] keywords. Many 
of these publications are free, which creates the opportunity to mine relationship between 
biological entities to provide a larger view of biological pathways. Generic search 
engines such as Google, Yahoo, Bing, etc. are not good enough for biological 
information retrieval. In particular, there is demand for semantic or concept based search, 
rather than keyword based search. Hence, there already have been some to build search 
engines to find publications according to a domain-specific concept [5]. FACTA [6] is a 
text search engine for MEDLINE abstracts, which is designed to browse biomedical 
concepts including gene, protein, disease, enzyme and chemical compounds. FACTA 
ranks the biomedical components according to co-occurrence statistics with the query. 
PolySearch [7] is another comprehensive biomedical search engine, which ranks 
biomedical concepts integrating multiple information sources including PubMed, Online 
Mendelian Inheritance in Man (OMIM) [8], DrugBank [9], Swiss-Prot [10], Human 
Metabolome Database (HMDB) [11], Human Protein Reference Database (HPRD) [12] 
and General Anxiety Disorder (GAD) [13]. Chilibot [14] is a NLP-based text mining 
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approach which constructs content-rich relationship networks among biological concepts 
including gene, protein and drugs. It is also capable of generating new potential 
hypothesis. GeneIndexer [15] performs latent semantic indexing on MEDLINE abstracts 
to rank genes according to user query. Furthermore, it shows the topology containing the 
genes of interest. Pubmatrix [16] is an intuitive multiplex comparison system, which 
compared two sets of biological concepts using co-occurrence in MEDLINE abstracts. 
Textpresso [17] is an ontology-based information retrieval and extraction system for 
biological literature. It performs literature mining on biological concepts including gene, 
allele, cell components, phenotype etc. The authors hypothesized that a pair of biological 
concepts occurring in the same sentence are associated or regulated through a biological 
process. They performed literature parsing on full text articles, which increased the recall 
from 45% to 95%, but precision is decreased from 52% to 30%. There are several text 
mining approaches to explore protein-protein interaction [18-25] and protein-disease 
interaction [26,27].  
There has been number of effort in pharmacological literature mining as well. J. 
Chang et al. [28] used sentence level co-occurrence method to mine and characterize 
gene-drug relationships from MEDLINE abstracts. The method resulted in 60% precision 
and 51% recall. Roberto et al. [29] performed data mining to identify drug-drug 
interactions. Y. Garten et al. [30] developed a literature mining tool to find the ranking of 
genes related to a particular drug. The precision of the tool found to be 77.4%. The 
pharmacogenomic knowledge base has been used to create semantic networks [31]. The 
system uses sentence level parsing of full text of scientific articles. The precision is found 
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to be 70-87.7%. S. Erten et al. [32] showed a method to find the similarity between 
biological entities according to topological similarity.  
 PharmGKB [33,34] is a comprehensive resource for pharmacogenomics 
including impact of genetic variation on drug response, relationship among genes, drugs 
and diseases, etc. The ultimate goal of PharmGKB is to create the knowledge base on 
pharmacogenes, their variations, their pharmacokeinetics and pharmacodynamic 
pathways, and their effects on drug-related phenotypes to achieve personalized medicine 
[35]. PharmGKB contains a vocabulary facilitating semantic annotation of biological 
literature. The vocabulary is divided into five main categories: (i) Clinical outcome, (ii) 
Pharmacodynamics and drug responses, (iii) Pharmacokinetics, (iv) Molecular and 
cellular functional assays, and (v) Genotype. 
Though most of the researchers depend on MEDLINE for biological information 
retrieval and perform literature mining, there is a demand to integrate several 
heterogeneous data sources to provide better information extraction. Intelligent Data 
Understanding System (IDUS) [36] is a query based information retrieval system 
semantically integrating distributed and heterogeneous biological data sources. S. 
Suwannaroj et al. [37] developed a framework to facilitate automatic construction of gene 
subnetworks by integrating multiple biological data sources.  
Tree based parsing method has also been applied to MEDLINE abstract literature. 
Y. Mijao et al. [38] developed a tree based semantic retrieval system to identify the 




1.4 Organization of the Thesis 
Chapter 2 is going to present the basics of latent semantic analysis and the 
associated parameters such as corpus, dictionary, term-document matrix, dimension, 
similarity measure, and systemic bias. 
Chapter 3 is going to present our methodology how to choose pharmacological 
entities for literature mining. We hypothesized that there are lots of redundant and less 
informative pharmacological entities, which are responsible for making the associated 
model noisy and skewed. We explored the properties of entities and showed a statistical 
method to select informative and sufficient ones. Though we performed our experiment 
on pharmacological literature, but our method can be applied to any set of entities 
represented as tree structure. Proper choice of entities partially addresses the systemic 
bias issue as discussed earlier in this chapter. 
Chapter 4 will mostly discuss our distributed data mining framework to perform 
pharmacological literature mining. We showed how topic based clustering can address 
the scalability and systemic bias issue in a literature mining framework. We also showed 
why distributed model is computationally efficient and feasible. We articulated the 
natural language processing issue to process the corpus and generate the multi-gram 
dictionary. We presented a normalized database design to store literature data from 
PubMed efficiently. Furthermore, we presented our pharmacological web analysis tool 
called PharmNet, which can analyze the interaction between disease, cellular compounds, 
biological factors, etc. as a network diagram. 
Chapter 5 represents the results of our experiments using the web analysis tool 
PharmNet. We showed how distributed model and proper choice of clustering and 
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similarity measure can address systemic bias issue and provide better information 
retrieval. Furthermore, we showed how multi-gram model improves the performance of 
latent semantic analysis for biological literature mining. We performed the validation of 























Latent Semantic Analysis 
 
2.1 Model 
Latent Semantic Analysis (LSA) [39] is an information retrieval technique used to 
analyze relationship among a set of documents. Usually, the set of documents is 
represented as term-document matrix which describes the occurrences of terms in 
documents. LSA performs factorization technique, such as Singular Value 
Decomposition (SVD) to transform the term-document matrix into low rank 
approximation. The first few eigen-vectors and their corresponding singular values 
capture most of the information in the term-document matrix. Using this idea, the 
dimensionality of the term-document matrix is reduced. This method re-distributes the 
weights in the original term-document matrix, which helps to get indirect association 
between query and document along with direct association. Hence, LSA is considered to 
be a technique capable of revealing semantic meaning of a term. 
Suppose   is a term-document matrix with   documents and   terms. Then,   can 
be factorized using SVD resulting,       , where      and      are eigen-vectors 
and                is a diagonal matrix indicating the singular values. However, it is 
possible to choose an approximation of  , denoted as                , where    . 
This results the approximation of  , denoted as      and approximation of  , denoted as 
    . Hence, the approximation of   is obtained as          . The dimension of each 
vector in   is reduced to   by projecting    into    resulting new projected matrix 
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      . Figure 2.1 illustrates how to choose the approximated eigen-vectors and 





Figure 2.1. Dimension reduction after SVD.   is factorized to eigen-vectors  ,   and 
singular values   after performing SVD. Low rank approximation is achieved through 
reduction to   dimension, producing approximate eigen-vectors   ,    and singular values 




Proper choice of reduced dimension   is an empirical issue. One of the methods is 
to select   in such a way that first   singular values capture 97% of the values of all 
singular values, i.e.             
 
   
 
    [40]. An alternative selection of   can be 
achieved by the inequality           [40]. In our framework, we considered 300 to 
be the reduced dimension, which captures about 97% of the information in our data. 
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LSA has very important applications in bioinformatics. There are several bioinformatics 
tools which use LSA as a tool for information retrieval. For instance, GeneIndexer [15] is 
a LSA based framework, which finds the ranking of genes according to a user query. The 
usage of LSA is useful to discover unknown association between biological components, 
such as gene, protein, transcription factor, enzyme, etc. due to its capability of identifying 
indirect association. 
2.1.1 Global Model 
In global model, latent semantic analysis is performed on all documents at a time. 
The advantage of global model is that, it can reveal direct and indirect association 
between all documents at a time. However, when the number of documents become huge, 
then global model is no longer feasible due to several reasons. Firstly, the computation 
time of SVD is              , when SVD is performed on a    matrix. When 
the number of documents ( ) becomes very high, it takes a huge amount of time to 
generate the model. Secondly, the hardware is not capable of loading a matrix into 
memory when the dimension is more than a particular threshold. Hence, large numbers of 
documents may not be able to be processed by the hardware resource. Finally, the global 
model generated using LSA observes systemic bias problems due to the presence of both 
very small and very large documents in a single model. We will address this issue more 
elaborately in section 2.3. 
2.1.2 Distributed Model 
Along with the computational limitation, global latent semantic analysis is an 
unsupervised method, which ignores the class discrimination inside the model. There are 
already several efforts to perform latent semantic analysis in a distributed manner. S. 
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Vigna [41] proposed a distributed and large-scale latent semantic analysis using index 
interpolation. Except the distributed computation, the resultant model is global and fails 
to address the class discrimination inside the model. T. Liu et al. [42] proposed a Local 
Relevancy Weighted LSI method, which distributes the training documents into different 
classes according the relevancy to that class and performs SVD separately. It assigned 
empirical weights to each local semantic space according to its contribution to the global 
space. There exists tradeoff between different sized local spaces. Large local spaces are 
capable of discriminating the documents sufficiently. But the model also may contain 
several non-relevant documents creating noise and systemic bias. On the other hand, 
small local spaces are less noisy, but observe lack of information in the documents. 
Hence, there is an issue of the class size parameter tuning. 
Pharmacological literature data is growing very fast. Moreover, it consists of 
different known classes of documents. Both these criteria motivated us to build a 
distributed model for pharmacological literature mining. Chapter 4 discusses how the 
pattern and structure of pharmacological data can be modeled in a distributed manner. 
Our result shows the reduction of systemic bias due to usage of distributed model. 
2.2 Model Parameters 
The performance of LSA depends on proper choice of parameters, such as corpus, 
dictionary, tf-idf matrix, dimension, factorization technique, similarity measure etc. In 
this thesis, we are focusing on building a framework for pharmacological literature 
mining. Hence, our corpus is fixed and cannot be used as parameter. Furthermore, we 
used only SVD as factorization technique. The next sections focus on brief discussions 




Usually each row in the term-document matrix (used for model generation) 
corresponds to a word in a dictionary. The dictionary should be representative of 
keywords of the corpus used for literature mining. There are different ways to choose or 
generate dictionary. If the domain knowledge of the corpus is known and a standard 
dictionary of that domain is available, then the dictionary may be chosen for model 
generation. Otherwise, the dictionary may need to be generated from the corpus. For this 
purpose, the dictionary is generated by parsing the words in the corpus and performing 
stemming, stop word removal and other natural language processing techniques.  
In this thesis, we used Medical Subject Headings (MeSH) vocabulary to create a 
dictionary for pharmacological literature mining. We used some pre-processing 
techniques (motivated by the organization of biological term structure) to generate a 
multi-gram dictionary. The details of dictionary generation techniques will be discussed 
in section 4.1. 
2.2.2 Term-Document Matrix 
Term-document matrix represents the organization, importance and co-occurrence 
of terms in a collection of documents. The set of terms is chosen from the dictionary, 
which may be a standard dictionary or may be generated from the corpus using natural 
language processing techniques. Usually the term-document matrix is represented by the 
Term Frequency (TF) for each term-document pair weighted by the corresponding term 
importance, known as Inverse Document Frequency (IDF). The hypothesis behind term 
importance is that highly occurred terms are considered as less important and vice versa.  
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Though there are several different ways to construct the TF-IDF matrix, we applied 
linear, log linear, smoothing and inquery methods for TF-IDF matrix construction due to 
relevance to our literature mining process. We presented a brief discussion of these 
matrix construction techniques in the following sections. 
2.2.2.1 Linear 
The technique represents the most conventional way to generate the TF-IDF 
matrix. The term frequency of term   in document   is defined by         , where     
indicates the number of occurrence of term   in document  . However, term frequency 
may be normalized by the number of occurrence of all term represented as,      
   
     
. 
The term frequency also may be normalized by the number of occurrence of the 
maximum occurred term represented as,             . 
Inverse document frequency is defined by         
   
         
, where     indicates total 
number of documents in the corpus and           indicates the number of documents 
where term   appears. To avoid divide by zero condition, inverse document frequency 
also may be represented as,         
   
           
. Here,      is inversely proportional to 
           , which follows the general hypothesis by decreasing term importance of 
highly occurred terms and vice versa. Finally, each cell of TF-IDF matrix is computed as, 
                  . 
2.2.2.2 Log Linear 
TF-IDF construction technique discussed in the previous section gives too much 
importance to a term in a document, if the term occurrence is very high. Log linear 
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technique reduces this biasness by normalizing the term frequency to logarithmic scale. 
Hence, term frequency is defined by       
                 
           
 . This technique 
works better in the presence of different sized documents in a single model. For 
pharmacological literature mining, we found log linear method of TF-IDF construction to 
be most useful due to different document sizes. 
2.2.2.3 Smoothing 
We know that latent semantic analysis finds second order occurrence between 
terms using re-distribution of weights through matrix factorization. When a matrix is very 
sparse, re-distribution may change the meaning of the terms dramatically. In this 
circumstance, smoothing technique may be useful to get rid of sparseness of the matrix. 
Smoothing technique defines term frequency as,              
   
       
, where 
     . The choice of   is empirical and depends on the sparseness of the matrix.  
2.2.2.4 Inquery 
Inquery [43] was first used retrieve ranked list of documents in a search engine. In 
this technique, each cell of TF-IDF matrix is defined as,                  
           
            
                
  
    
   
  
 
      
, where    
                
  
       
          
 . Usage 
of logarithmic scale reduces the biasness towards highly occurred terms. Furthermore, 
maximum number of occurrences of a term is limited to 25, which restricts the biasness 
towards highly occurred terms over a certain limit. Smoothing technique is also applied 




One of the purposes to apply matrix factorization technique, such as latent 
semantic analysis on term-document matrix, is to reduce the dimensionality of the matrix. 
Dimension should be reduced carefully so that the information in the original matrix is 
retained to a certain limit. There are several methods to choose the number of reduced 
dimension. One way is to choose first   eigen-vectors and singular values so that 
            
 
   
 
    follows. An alternative way is to choose   so that       
    satisfies. However, P. Kanerva [44] showed that 300 dimensions are sufficient to 
keep the model informative. 
2.2.4 Similarity Measure 
In an information retrieval framework, similarity measure technique is required to 
find the ranking of documents for a particular query. A vector space model required 
similarity or distance measure between pair of vectors. There are several methods to 
measure similarity between vectors such as Euclidian distance, cosine similarity, 
correntropy similarity, Mahalanobis distance etc. There are some semantic similarity 
measure techniques as well. The next few sections will discuss different similarity 
measure techniques, which are relevant to this thesis. 
2.2.4.1 Cosine Similarity 
Cosine similarity measures the similarity between two vectors in terms of the 
cosine of the angle between them. The similarity is normalized between 1 and -1. If   
and   are two vectors, then cosine similarity between them is measured by 
            
  
          
. If                and               , then     
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   . Therefore, the equation of cosine 
similarity can be re-written as,             
     
 
   
    
  
       
  
   
. Figure 2.2 illustrates the 





Figure 2.2. Cosine similarity. If   indicates the angle between two vectors   and  , then 




The advantage of cosine similarity lies in its computational efficiency. If the 
dimension of the vectors is  , then the computational time of cosine similarity calculation 
is     . Furthermore, the magnitude of each vector may be pre-computed to achieve 
faster computation. The disadvantage of this similarity is its susceptibility to systemic 
bias. Due to this bias, a vector corresponding to a document with large number of 
literature provides lower statistical similarity against a query. In contrast, a vector 
corresponding to a document with few literatures gives higher statistical similarity. Later 
we will show that proper choice of clustering can resolve the systemic bias issue. 
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2.2.4.2 Correntropy Similarity 
Correntropy is a non-linear similarity measure. It came from a novel functional 
measure, called correntropy coefficient [45] to characterize dynamical interdependencies 
between interacting systems. It captures the non-linear interdependencies between 
random variables. It takes advantage of its non-linearity by dynamically changing the 
order statistics. Correntropy is equivalent to higher order statistics for dense data points 
and lower order statistics for sparse data points. For instance, correntropy is equivalent to 
2-norm distance for sparse data points. It is equivalent to 1-norm when the data points are 
a bit sparse and zero-norm when they are very sparse. In this way, it reduces the biasness 
towards noisy or irregular data points.  





                 
 
 
          
 
  
         
 
     
 
   
        
         
 
     
 
  
        
         
 







Where,               
 ,               
 ,   is the dimension of the 
vectors and        
 
    
     
      
   
  defines the Gaussian kernel of the underlying 
distribution.   is the only parameter to be chosen. J. Xu et al. showed that the best 
performance can be found by choosing              . Here,                , 
where    indicates the standard deviation of the data points. The value of   is restricted 
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up to 1.34, which ensures the standard deviation of the Gaussian kernel to be within 25th 
and 75th percentile.  
If we analyze the definition of                 , then 
 
  
         
 
      
indicates the cross information potential between   and  , 
 
  
         
 
      indicates 
the information potential for  , and 
 
  
         
 
      indicates the information potential 
for  . 
With   dimensionality, the computation time of correntropy similarity is      , 
which is slight more costly than cosine similarity. 
2.3 Systemic Bias 
In general, systemic bias is the tendency of a system or a process to favor some 
particular outcome. In an information retrieval model, systemic bias indicates the 
biasness towards a particular pattern of documents. There are several reasons behind 
systemic bias inside a model. Firstly, skewed dataset may cause systemic bias. The 
existence of very small or very large documents inside a model is one of the ways how 
skewed dataset may arise. Secondly, the existence of different classes of dataset inside 
the same model may cause systemic bias.  
The structure of pharmacological literature data is responsible for the existence of 
systemic bias inside the data model. Skewed dataset causes systemic bias in 
pharmacological literature model. There are some pharmacological entities, which are 
annotated in a few scientific articles. For instance, Sodium Nitrite is a chemical which is 
annotated only in 1,004 MEDLINE articles. In contrast, there are some entities, which are 
annotated in large number of articles. For instance, Vitamin A is annotated in 24,782 
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MEDLINE articles. Again, the existence of different classes of data causes systemic bias 
inside pharmacological literature model. For instance, our dataset is divided into several 
clusters, such as proteins, biological factors, chemical compounds, enzymes, hormones, 





Figure 2.3. Systemic bias due to different sized documents. The existence of different 
sized documents causes systemic bias. The cosine similarities between query and a set of 
documents are found to be different due to different document size, assuming that each 
document contains the query word. If we consider largest possible document size to be 
100, then leftmost document (size 1) is the smallest and rightmost document (size 100) is 





Now the question is why should we care for systemic bias? Systemic bias harms 
in two major ways. Firstly, it changes the importance of documents. If an information 
retrieval model contains some very small and very large documents, then systemic bias 
issue arises. If we compare a query against the set of documents in the model using a 
similarity measure, then smaller documents tend to provide higher similarity score 
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comparing to the original one and larger documents tend to provide lower similarity 
score. Figure 2.3 indicates the cosine similarity between query vector and different sized 
document vectors, after performing latent semantic analysis on linear TF-IDF matrix (see 
section 2.2.2.1). Though all documents contain the query word, it is quite evident that the 
similarity score decreases, as the size of document increases. The leftmost document is 
the smallest one containing only one word (here, the query word) and the rightmost 





Figure 2.4. Systemic bias in pharmacology corpus. The existence of different sized 
documents causes systemic bias in pharmacology corpus in this study. The cosine 
similarities between query and a set of documents are found to be different due to 
different document size, assuming that each document contains the query word. If we 
consider largest possible document size to be 100, then leftmost document (size 7) is the 
smallest in the corpus and rightmost document (size 47) is the largest in the corpus. The 




However, it is impractical for a document to have all words in the corpus. In our 
dataset, the smallest document has 2,457 words covering 7% of the words in the corpus 
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and the largest document has 17,094 words covering 47% of the words in the corpus. 
Hence, Figure 2.4 shows the clear picture of the systemic bias issue. 
Secondly, systemic bias may change the meaning of documents due to presence 
of different classes of documents in the same model. For instance, the pharmacology 
corpus, used in this study contains documents from different classes: chemical 
compounds, diagnosis, etc. As latent semantic analysis re-distributes weights, there is a 
potential risk to re-distribute irrelevant information. This scenario may change or modify 
the original meaning of the documents. 
In this study, we used model clustering technique to get rid of systemic bias 
problem. Firstly, model clustering reduces the skewness in the data. Then, it separates the 

















Identification of Pharmacological Entities 
 
Identification of pharmacological entities is necessary to perform literature 
mining on the text dataset. We chose MeSH as a primary source of pharmacological 
entities, as MEDLINE articles are annotated with MeSH keywords. However, the 
vocabulary includes many uninformative entities, including too generic, too specific, or 
redundant entities. This chapter presents a systematic method to identify informative 
pharmacological entities to ensure the quality of literature mining. We will see in chapter 
4 that proper selection of entities also take care of systemic bias issue. 
3.1 MeSH 
MeSH is abbreviated as Medical Subject Headings. It is the controlled vocabulary 
of U.S. National Library of Medicine (NLM). MEDLINE references are annotated with 
MeSH keywords, allowing faster and informative search in the database. One of the 
distinct features of MeSH vocabulary is its hierarchical structure. The terms located near 
the root are considered generic and the terms located near the leaves are considered 
specialized. The tree structure of MeSH vocabulary allows the terms to be dynamically 
categorized. Furthermore, new terms or new categories can be easily adopted. Figure 3.1 







Figure 3.1. Hierarchical structure of MeSH. The words in MeSH are organized in 
hierarchical manner. MeSH code tells the location of a word in the structure. For 
instance, the MeSH code of Amino Alcohols is D02.033.100, which says it evolved from 




There are total 52,545 terms in the 2011 MeSH vocabulary. They are classified 
into 16 major categories: (i) Anatomy, (ii) Organisms, (iii) Diseases, (iv) Chemical and 
Drugs, (v) Analytical, Diagnosis and Therapeutic Techniques and Equipments, (vi) 
Psychiatry and Psychology, (vii) Biological Sciences, (viii) Physical Sciences, (ix) 
Anthropology, Education, Sociology and Social Phenomena, (x) Technology and Food 
and Beverages, (xi) Humanities, (xii) Information Science, (xiii) Persons, (xiv) Health 
Care, (xv) Publication Characteristics, and (xvi) Geographic Locations. The MeSH 
terms are organized in 13 levels of the tree structure including the root. The tree does not 
have a balanced structure, implying non-uniform specificity of the MeSH terms occurring 
in the same level. The terms located close to the root, allow lot of branches and 
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considered to be generic. In contrast, the terms located close to the leaf, allow few 
branches and considered to be specific. However, each MeSH term has been allocated a 
MeSH ID, which indicates the classification of the term and its location in the tree as 
well. For instance, MeSH ID of Lactic Acid is D02.241.511.459.450, which indicates that 
it is term belong to Organic Chemicals category, which is located in the 5th level of the 
tree (considering root as level 0).  
In this study, we used MeSH vocabulary as a primary set of pharmacological 
entities due to its annotation with MEDLINE database. Furthermore, its hierarchical 
structure helped us to identify very generic and very specific. 
3.2 Pharmacological Entities 
We chose the terms in Chemical and Drugs, and Analytical, Diagnostic and 
Therapeutic Techniques and Equipment classes in MeSH vocabulary as a primary set of 
pharmacological entities, which constitutes of 23,475 terms. Chemical and Drugs is 
classified into 16 categories: (i) Inorganic Chemicals, (ii) Organic Chemicals, (iii) 
Heterocyclic Compounds, (iv) Polycyclic Compounds, (v) Macromolecular Substances, 
(vi) Hormones, Hormone Substitutes and Hormone Antagonists, (vii) Enzymes and 
Coenzyems, (viii) Carbohydrates, (ix) Lipids, (x) Amino Acids, Peptides and Proteins, 
(xi) Nucleic Acids, Nucleotides and Nucleosides, (xii) Complex Mixtures, (xiii) 
Biological Factors, (xiv) Biomedical and Dental Materials, (xv) Pharmaceutical 
Preparations and, (xvi) Chemical Actions and Uses. And, Analytical, Diagnosis and 
Therapeutic Techniques and Equipments is classified into 7 categories: (i) Diagnosis, (ii) 
Therapeutics, (iii) Anesthesia and Analgesia, (iv) Surgical Procedures, Operative, (v) 
Investigative Techniques, (vi) Dentistry, and (vii) Equipment and Supplies. 
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The features of pharmacological entities lie in their location in MeSH tree 
structure and their annotation in MEDLINE articles. In this study, we considered the 
features: size, level, depth, document ratio and sub-tree breadth. A short overview of the 
features is presented below: 
 Size: We defined the size of a pharmacological entity in terms of number of 
annotated articles in MEDLINE. For instance, the size of Sodium Nitrite is 1,004, 






Figure 3.2. Level of a pharmacological entity. The root is considered as level 0 in MeSH 




 Level: We defined the level of a pharmacological entity to be its distance with 
respect to the root in the MeSH tree. The definition clearly specifies the level of 
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root as 0. The level of Sodium Nitrite is 3, because its distance with respect to the 
root is 3. Similarly, the level of Vitamin A is 5. Though lower level value is 
considered as more generic and higher as more specific, the level is not really a 
standard measure of the specificity of a term due to the unbalanced MeSH tree 





Figure 3.3. Depth of a pharmacological entity. {D, E, G, H} have no descendents 
causing depth 0; {B, F} have only one generation descendants causing depth 1; {C} has 
two generation descendants causing depth 2; {A} has three generation descendants 




 Depth: We defined the depth of a pharmacological entity to be the largest of the 
distances with respect to its descendents. The definition clearly specifies the depth 
of each leaf node as 0, because they do not have any descendent. The depth of 
Sodium Nitrite is 0, as it is a leaf node. Again, the depth of Porins is 3, because it 
has 11 descendants and the largest distant descendant (Aquaporin 3 or Aquaporin 
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6) is located 3 nodes away. Lower depth value is considered as specific and 






Figure 3.4. Document ratio of a pharmacological entity. The ratio of size between B’s 




 Document ratio: We defined document ratio a pharmacological entity to be the 
ratio between the size of the entity and the size of its parent. It represents the 
specificity of an entity comparing to its parent entity. We can consider the 
document ratio of root node as 1, as it does not have any parent and it is very 
generic as well. In this study, we eliminated the entities in the first two levels. 
Therefore, the document ratio for all level 3 documents is 1. The minimum value 
of document ratio is 1, because an entity can’t be more generic compared to its 
parent entity. A lower value of document ratio of an entity indicates that the entity 
is not too specific compared to its parent. For instance, the document ratio of 
Vitamin A is 1.24, which indicates that it is not too specific compared to its parent 
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Retinoids. In contrast, a higher value of document ratio of an entity indicates that 
the entity is very specific compare to its parent. For instance, the document ratio 
of Receptors, Ige is 53.79, which indicates that it is very specific compared to its 






Figure 3.5. Sub-tree breadth of a pharmacological entity. The node A has 4 descendents 




 Sub-tree breadth: We defined the sub-tree breadth of a pharmacological entity to 
be the breadth of its descendants. It is measured as the ratio between the number 
of descendants and the depth of the entity. The sub-tree breadth of leaf nodes is 
considered as 0, as they do not have any descendant. A higher value of sub-tree 
breadth of an entity indicates that its descendants are densely located with a few 
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levels. For instance, the sub-tree breadth of Phenothiazines 20, because it has 20 
descendants only in 1 level. In contrast, a lower value of sub-tree breadth of an 
entity indicates that its descendants are spread through several levels. For 
instance, the sub-tree breadth of Retial Pigments is 1.33, because it has only 4 
descendants spread in 3 different levels. In this study, we did not find sub-tree 
breadth to be useful to identify pharmacological entities. However, this feature 
may be useful in similar studies on different dataset. Figure 3.5 illustrates the sub-
tree breadth of a pharmacological entity. 
Next few sections are going to explain three levels of selection methods: (i) 
window based selection, (ii) forest based selection, and (iii) specificity based selection, to 
choose proper pharmacological entities for literature mining.  
3.3 Window Based Selection 
As our goal is to eliminate very generic, very specific and redundant entities, we 
need to determine the boundaries of the quantitative features. We intend to find lower and 
upper boundaries of size, level, depth and document ratio. We defined window based 
selection as the selection of entities within the boundary of quantitative features. We 
primarily selected 23,475 pharmacological entities to perform window based selection. 
Next sub-sections are going to discuss the method to identify the boundaries for size, 
level, depth and document ratio of desired pharmacological entity. 
3.3.1 Boundary of Size 
As mentioned in section 3.2, the size of a pharmacological entity denotes the 
number of annotated articles in MEDLINE. To determine the boundaries of size, we 
plotted the distribution of size, as shown in Figure 3.6. It clearly shows that there are lots 
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of pharmacological entities having small size, which indicates a low number of annotated 
articles in MEDLINE. On the other hand, there are few entities having large size. Small 
sized entities are considered specific and large sized entities are considered generic. Now, 
there are 21,552 entities annotated in at most 20,000 articles, which covers 91.81% of all 
pharmacological entities. There are 21,855 entities annotated in at most 25,000 articles, 
which covers 93.10% of all pharmacological entities. There are 22,106 entities annotated 
in at most 30,000 articles, which covers 94.17% of all pharmacological entities. There are 
very few entities annotated in more than 25,000 articles, and we found most of them to be 
very generic by manual verification. For instance, Andibodies is annotated in 455,632 
articles, Blood Proteins is annotated in 870,983 articles which are very generic MeSH 





Figure 3.6. Distribution of size of pharmacological entities. There are lots of small sized 
entities and few large sized entities causing the curve to have exponential shape. 
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We hypothesize that very small sized entities are too specialized and fail to infer 
quality information. However, the lower boundary of the size is difficult to decide from 
the distribution of the size. We plotted the cumulative distribution of the size to get a 
better picture, as shown in Figure 3.7. The figure shows size only between 1 and 5,000, 





Figure 3.7. Cumulative distribution of size of pharmacological entities. There is sharp 
slope in the left side of the graph, as there are lots of small sized entities. In contrast, the 




According to our hypothesis, we are interested to find the point where the curve 
becomes reasonably smooth. Hence, we plotted the distribution of first order derivative of 




Figure 3.8. First order derivative of cumulative distribution of size. Left side of the graph 




Figure 3.8 clearly shows that the curve is very sharp between 1 and 1,000 of the 
x-axis. After that, the curve turns out to be smooth. Hence, 1,000 seems to be the 
potential lower boundary of entity size. However, we plotted the distribution of second 
order derivative of the cumulative entities with respect to size, as shown in Figure 3.9, to 
validate our assumption. 
Figure 3.9 clearly shows that there is a zero crossing very close to 1,000. It 
interprets that the distribution of size becomes smooth nearly at 1,000. Therefore, we 




Figure 3.9. Second order derivative of cumulative distribution of size. There is a zero-




3.3.2 Boundary of Level 
Our primarily selected pharmacological entities are spanned over 11 levels of 
MeSH tree structure. The first level contains 23 terms, which basically defines the 
categories, such as Inorganic Chemicals, Organic Chemicals etc. Therefore, we excluded 
the terms in the first level, as they are very generic. The second level contains 540 terms, 
which mostly defines the sub-categories, such as Acids, Alkalies, etc. Hence, we also 
excluded the terms in the second level, being generic as well. We plotted the distribution 
of level, as shown in Figure 3.10. The figure approximately follows Gaussian distribution 
where entities between level 3 and 8 cover 97% of all pharmacological entities (see non-
shaded portion of Figure 3.10). We consider the levels less than 3 to be very generic and 




Figure 3.10. Distribution of level of pharmacological entities. The distribution of level 
observed to be bell-shaped. Most of the entities are located in mid levels. 97% of the 
entities are located between level 3 and 8. The entities in shaded portion of the graph are 




3.3.3 Boundary of Depth 
The pharmacological entities are spanned over 10 different depths (between 0 and 
9) in the MeSH tree structure. The distribution of depth, as shown in Figure 3.11, shows 
the significance of the first few depths. It is quite clear that the entities between depth 0 
and 3 covers the 98% of all pharmacological entities. The entities having higher depth are 
considered to be very generic. For instance, Chromosomes at level 4, Kidney at level 5, 
Genome at level 6, Blood Cells at level 7, Brain at level 8 etc are considered to be very 




Figure 3.11. Distribution of depth of pharmacological entities. The distribution of depth 
observed to be exponential shaped. Most of the entities are located on the left side. 98% 
of the total entities are located between depth 0 and 3. The shaded portion of the graph 









Table 3.1. Lower and upper boundaries of quantitative feature of pharmacological 
entities: size, level and depth. 
Quantitative feature Lower boundary Upper boundary 
Size 1,000 25,000 
Level 3 8 




3.3.4 Boundary of Document Ratio 
Unlike size, level, and depth, global boundary is not going to work very well for 
document ratio, as the entities at different level shows different document ratio 
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properties. Hence, we calculated the mean (   ) and variance (   ) of document ratio at 
different levels, as shown in Table 3.2. According to our level window, we calculated 
mean and variance at levels between 3 and 8. However, being the first level within our 
window each document ratio at level 3 is 1 and insignificant to calculate any statistics. 
We considered         at each level to be the upper boundary of document ration. Any 




Table 3.2. Mean and variance of document ratio of pharmacological entities at different 
levels in the MeSH structure. 
Level                 
4 52.54 101.37 153.91 
5 21.31 40.04 61.35 
6 14.56 27.99 42.55 
7 12.81 39.36 52.17 




After performing window based selection on primarily selected 23,475 
pharmacological entities, we obtain 9,634 entities within the window. We will perform 
forest based selection (see section 3.4) on these entities to obtain more useful entities. 
3.4 Forest Based Selection 
After performing window based selection, the initial MeSH tree structure is 
broken into several forests, as shown in Figure 3.12. We found 9,634 pharmacological 
entities distributed over 5,538 trees creating a forest. Here, the heights of 93.54% trees 
are at most 1, where 66.74% trees contain only one node (the root). As most of the trees 
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are very short, we hypothesize that choosing only the roots of the trees is going to be 
sufficient. Due to hierarchical structure, the roots are going to represent the literature 
belong to its descendants. Furthermore, the window based selection, performed in the 





Figure 3.12. Forest based selection. After performing window based selection, the 
MeSH tree is segmented into several isolated trees. Forest based selection chooses each 




3.5 Redundancy Elimination 
MeSH vocabulary allows a term to appear in different locations of MeSH tree, as 
a term may have different meaning or function at different location. For instance, 2-
Methylpiperazine appears 3 times in MeSH vocabulary, because it belongs to Organic 
Chemical, 1-ring Heterocyclic Compounds and 2-ring Heterocyclic Compounds 
categories at the same time. Regardless of their different meaning or function, they are 
annotated almost in the same articles in MEDLINE. Hence, the redundant terms are 
useless in our literature mining framework. We performed redundancy elimination on 




3.6 Specificity Based Selection 
We consider pharmacological entities with small size as specific and large size to 
be generic, low depth as specific and high depth as generic, low document ratio as 
generic and high document as generic. Hence, the specificity of an entity is dependent on 
its feature specificities. An entity is obviously going to be very specific, if all the features 
show high specificity and vice versa. This assumption motivated us to represent the 








Here,   is the specificity of an entity,    is the size specificity,    is the depth 
specificity,     is the document ratio specificity,    is the weight for size specificity,    
is the weight for depth specificity and     is the document ratio specificity. 




      
      
       
 
 
, where   is a 
feature,    is the value of a feature,     is the most specific value of a feature and     is 
the most generic value of a feature. Table 3.3 shows the most specific and generic values 
of each feature, which come from the window based selection (see section 3.3). 
    is a non-linear function, which is normalized between 0 and 1. Now,      
indicates the most specific value of an entity and      indicates the most generic value. 
Figure 3.13 shows the characteristics of   , which clearly indicates that    is maximum 
when        and    is minimum when       . 
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Table 3.3. Most specific and generic values of quantitative feature of pharmacological 
entities: size, depth and document ratio. 
Feature ( ) Most specific value (   ) Most generic value (   ) 
Size 1000 25000 
Depth 0 3 





Figure 3.13. Specificity function of a feature. It is a non-linear function, where the most 
specific value (fsv) of a feature has specificity 1, as shown on the left side and the most 




As each feature specific    is normalized between 0 and 1, the condition      
  ensures the specificity   to be normalized between 0 and 1 as well. The choice of each 
weight    is empirical and depends on the characteristics of the dataset. We choose    as 
0.25,    as 0.25 and     as 0.5. The distribution of   is shown as Figure 3.14. 
From Figure 3.14, it is quite clear that there are few entities between specificity 0 
and 0.2, which are very generic. Again, there are few entities between specificity 0.6 and 
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1, which are very specific. For instance, the specificity of Carbonic Acid is 0.07, which is 





Figure 3.14. Distribution of specificity. Though the distribution seems to be random and 
non-parametric, it observes most of the entities between 0.2 and 0.6. The shaded portion 




The usage of specificity function gives us 2,807 informative pharmacological 
entities, which will be used to develop pharmacological literature mining framework, as 










Distributed Model for Pharmacological Literature Mining 
 
This chapter describes a distributed literature mining framework for 
pharmacological knowledge analysis and discovery. Our method includes dictionary 
generation, data extraction, literature mining model and a web analysis tool, called 
PharmNet.  
4.1 Dictionary 
Latent semantic analysis (LSA) is a vector based model, which treats each word 
in the literature independently. It causes the multi-gram meaning of a keyword to be lost. 
However, the multi-gram meaning is important in many biological keywords. For 
instance, the meaning of Blood Cancer is lost if Blood and Cancer are treated 
independently. Multi-gram dictionary can preserve the multi-gram meaning in a bag-of-
word model. This motivated us to generate a multi-gram dictionary for pharmacological 
literature mining. We used MeSH vocabulary to construct dictionary. We found that a 3-
gram dictionary is sufficient to store most of the multi-gram biological words. The 
following steps describe the method of our dictionary generation: 
 We extracted 1-gram words by separating each word from each MeSH term. For 
instance, we extracted Inhibitory, Amino and Acid from the MeSH term Inhibitory 
amino acid. We eliminated the stop words from the 1-gram word list, such as and, 
is, are etc. We also eliminated the numbers. In this process, we obtained 19,622 
unique 1-gram words.  
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 We extracted 2-gram words by choosing each two consecutive words from each 
MeSH term. For instance, we extracted Inhibitory Amino and Amino Acid from 
the MeSH term Inhibitory amino acid. This procedure ensured the biological 
meaning of each 2-gram word. We eliminated the words starting with a stop 
word. However, we allowed stop word in the second position. Biologically some 
words can’t occur in the last position of a 2-gram word, such as 3’, 5’ etc. We 
eliminated the words, which ended with these words. In this process, we obtained 
14,700 unique 2-gram words. 
 We extracted 3-gram words by choosing each three consecutive words from each 
MeSH term. For instance, we extracted Inhibitory Amino Acid, as it occurs as a 
MeSH term. As described in the earlier step, we eliminated words with first 
occurrence of stop words and last occurrence of biologically meaningless words. 
In this process, we obtained 4,785 unique 3-gram words. 
 We combined all 1-gram, 2-gram and 3-gram words generated above, resulting 
39,107 words. We crosschecked these words with our literature corpus to 
eliminate noisy words. The final dictionary consists of 36,558 words. 
4.2 Data Extraction 
We developed an automated tool to extract pharmacological literature dataset 
from PubMed into a normalized MySQL database. The tool is machine and platform 
independent and able to run on high speed server allowing maximum efficiency in data 
extraction. Though we extracted pharmacological literature for our purpose, it is possible 




The tool allows configuring the following input parameters:  
 URL: This is the URL of the system from where literature data needs to be 
extracted. We used the URL http://www.ncbi.nlm.nih.gov/entrez/eutils to extract 
our dataset. 
 Database: This is the name of the database in the URL from where the data needs 
to be extracted. We extracted data from pubmed database. 
 Starting year: This is the starting year of the published articles. We used 1950 as 
the starting year. 
 Ending year: This is the ending year of the published articles. We used the 
current year (2011) as the ending year. 
 Maximum number of articles: This indicates the maximum number of articles 
to be extracted for each pharmacological entity. We set this parameter to be 
unlimited. 
 Block size: This indicates the block size of articles fetched from PubMed at a 
time. We used a block size of 200 according to the NCBI rule. 
Our database consists of 3 tables: (i) PharmacologicalEntity, (ii) 
PubmedLiterature, and (iii) PharmaPubmed. The relationship between these tables is 
shown as E-R diagram in Figure 4.1. The database design is normalized, which gets rid of 
redundant and inconsistent data. 
PharmacologicalEntity consists of 6 fields: id, name, code, fullpath, year and 
status. Each row in this table describes a pharmacological entity. Here, id is the primary 
key; name indicates the name of pharmacological entity; code is its MeSH ID; fullpath 




Figure 4.1. E-R diagram of the database design. The database consists of three tables: 
PharmacologicalEntity, PharmaPubmed and PubmedLiterature. PharmaPubmed is a 





PubmedLiterature consists of 5 fields: id, year, title, abstract and meshheading. 
Each row in this table describes an article in PubMed. Here, id is the primary key; title 
and abstract are self-explanatory; year is the publication year of the article; meshheading 
is the MeSH annotations in the article. However, we did not meshheading in this study 
and preserved for future purpose. 
PharmaPubmed consists of 2 fields: pharmaid and pubmedid. Each row in this 
table represents the linkage between PharmacologicalEntity and PubmedLiterature. 
pharmaid is the foreign key to id in PharmacologicalEntity and pubmedid is the foreign 
key to id in PubmedLiterature. Both these fields constitute the primary key together. 
PubMed stores literature data in XML format. Therefore, we developed an XML 
parser to parse and extract pubmedid, title, abstract, year and meshheading from PubMed 
article and convert into relational database format. We extracted 7,376,608 literature 
records from PubMed using this tool. There are 17,607,560 linkages between these 
records and pharmacological entities.  
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We designed the tool in such a way that it extracts data in slow speed during 
office hours and high speed during non-office hours, weekends and holidays. We 
intentionally reduced the data extraction rate during office hours to ensure the safety of 
PubMed. 
4.3 Distributed Latent Semantic Analysis 
Distributed LSA model can overcome the computational limitation and systemic 
bias problem of global LSA. Distributed model requires the global model to be clustered 
into local models. Then latent semantic analysis is performed on each local model 






Figure 4.2. Distributed latent semantic analysis. The global model is clustered into 
several local models to perform latent semantic analysis independently. 
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The global model   is vertically partitioned into   local models           , so 
that               . Latent semantic analysis is performed on each local model    
separately. If the reduced dimension is  , then each encoding matrix    is approximated 
to   
 . Then we get each local projected matrix      
 
 
  . Finally, the global project 
matrix is restructured as,                  , where each    indicates the weight 
belong to local model   . However, this model requires same reduced dimension   for 
each local model. 
LSA infers the second order co-occurrence by re-distribution of weights. Model 
clustering results the loss of second order co-occurrence between the entities of separate 
clusters. However, clustering also prevents inferring wrong co-occurrence between 
irrelevant entities, if they are separated properly into different clusters. Therefore, the 
quality of distributed model depends on the way of clustering. In this study, we 
considered three ways of model clustering: (i) clustering by maximum mutual 
independence, (ii) clustering by entity size, and (iii) clustering by topic. 
i. Clustering by maximum mutual independence: This technique clusters the 
entities so that mutual independence between each pair of clusters is maximum. 
Application of traditional clustering techniques, such as k-means, hierarchical, 
DBSCAN etc can ensure the maximum mutual independence between clusters. 
This method can cluster relevant entities together and separate irrelevant entities 
into different clusters. The main drawback of this method lies in its computational 
inefficiency, as the dimension of the vectors is very high (number of words in the 









Figure 4.3. Different clustering techniques to produce local models. This figure shows 3 
clustering methods: (a) standard clustering, (b) clustering according to document size, 




ii. Clustering by entity size: To overcome the computational inefficiency of the 
earlier clustering method, entity size may be used for clustering the entities. This 
method ensures all the entities in a same cluster to have similar size. We know 
that one of the major reasons for systemic bias is the existence of very small and 
very large entities in a single model. However, clustering according to entity size 
reduces this systemic bias. The main drawback of this method lies in its inability 
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to keep relevant entities in a single cluster and separate irrelevant entities into 
different ones. Figure 4.3(b) illustrates the architecture of this clustering method. 
iii. Clustering by topic: This method clusters entities according to know 
classification of the dataset. Pharmacological entities belong to known 
classifications, such as chemical compounds, biological factors, diagnosis, 
procedures etc. This method clusters relevant documents together and ensure 
higher mutual independence between clusters. Moreover, the computational time 
of this method is very efficient. The main drawback of this method is that it fails 
to address the possible relationship between two entities in two different classes. 
Figure 4.3(c) illustrates the architecture of this clustering method. 
Due to known classification of pharmacological entities, we used clustering by 
topic in this study. We clustered the entities into 2 different groups: Chemical 
Compounds and Biological Factors and Techniques. Here, Chemical Compounds 
consists of 1,672 entities, which are belong to Inorganic Chemicals, Organic Chemicals, 
Heterocyclic Compounds, Polycyclic Compounds, Macromolecular Substances, 
Hormones, Hormone Substitutes and Hormone Antagonists, Enzymes and Coenzymes, 
Carbohydrates, Lipids, Amino Acids, Peptides and Proteins, Nucleic Acids, Nucleotides 
and Nucleosides and Complex Mixtures categories in the MeSH vocabulary. On the other 
hand, Biological Factors and Techniques consists of 1,135 entities, which are belong to 
Biological Factors, Biomedical and Dental Materials, Pharmaceutical Preparations, 
Chemical Actions and Uses, Diagnosis, Therapeutics, Anesthesia and Analgesia, 
Surgical Procedures, Operative, Investigative Techniques, Dentistry and Equipment and 
Supplies categories in the MeSH vocabulary. We used log linear method to generate TF-
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IDF matrix (see section 2.2.2.2) for each local model. We assumed uniform weight for 
each local space. Distributed method requires same reduced dimension for each local 










4.4 PharmNet: A Pharmacological Literature Mining Framework 
We developed a web-based framework for pharmacological literature mining, 
called PharmNet (Pharmacological Network). It uses the model generated using 
distributed LSA (see section 4.3) to facilitate information retrieval and network 
visualization. The web application is written in Java and hosted at 
http://141.225.166.104:8080/pharma. Current version of PharmNet is free to use and does 
not require any authentication. The main goal of this application is to explore the 
relationship between pharmacological entities using network visualization. It allows the 
user to visualize the pathway among the entities of interest. Therefore, PharmNet is a 
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useful framework for pharmacology researchers to design a new hypothesis. Figure 4.4 
illustrates the homepage of the web application. The method to compute association and 





Figure 4.5. Information retrieval using PharmNet. It returns the associated 
pharmacological entities against a query. This example shows the returned entities 




4.4.1 Information Retrieval in PharmNet 
PharmNet find the associations between a query and pharmacological entities 
using a query model. When user enters a query, the system transforms the query   into a 
vector  . However,   is projected into each local Eigen space by       
 
 
 . Then, 
local similarity vector    is constructed by calculating cosine similarity between     and 
each vector in reduced projected matrix   . Finally, similarity vector for all local space 
are merged together to construct the global similarity vector             . As 
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illustrated in Figure 4.5, we displayed the pharmacological entities according to 
decreasing order of similarity scores. We emphasized the scores having at least 0.3 as red 
to denote strong association. 
PharmNet allows domain specific searching facility. By default, it finds all 
pharmacological entities associated with the query. But choosing the category, it is 
possible to find the associated concepts belong to a certain domain. This version of 
PharmNet allows the user to search within 23 domains. Figure 4.6 illustrates a domain 





Figure 4.6. Categorical information retrieval using PharmNet. Using the category, it is 
possible to retrieve only domain specific information. This example shows the returned 







As the pharmacological entities come from MeSH vocabulary, users may be 
interested to see it MeSH hierarchy. Therefore, we provided a hyperlink to the right of 
each pharmacological entity to view its MeSH property. Figure 4.7 illustrates the 
visualization of MeSH hierarchy of an entity in PharmNet. The articles contributing to 
the similarity score is linked to PubMed, which is found in another hyperlink to the right 





Figure 4.7. MeSH structure of a pharmacological entity. This page shows the MeSH 
structure of a pharmacological entity. This example shows the MeSH structure of Valine, 







Figure 4.8. Network visualization using PharmNet. PharmNet shows the relationship 
between biological query words through pharmacological entities. This example shows 




4.4.2 Network Visualization in PharmNet 
This is a crucial functionality of PharmNet. This allows the user to visualize the 
relationship between queries through related pharmacological entities. Therefore, a user 
can understand how a set of query words construct a biological pathway involving the 
pharmacological entities. Figure 4.8 illustrates the network visualization in PharmNet. 
Each linkage between query and pharmacological entity is represented as association 
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strength in terms of similarity score and ranking. This example shows the relationship 
between three query words: Blood Pressure, Stroke and Tension. According to literature 
mined information, all these queries are connected through Plethysmography. Blood 
Pressure and Stroke are connected through Pulse, Blood Pressure Determination and 
Multicenter Studies as Topic. Finally, Blood Pressure and Tension are connected through 
NG-Nitroarginine Methyl Ester. However, it is also possible to build a network for a 
particular domain. This version allows 4 query words and 7 pharmacological entities to 




















This chapter presents the results and validation of this study. Our study improves 
the performance of information retrieval by utilization of a multi-gram dictionary in 
distributed model and reduction of systemic bias in the corpus. We provided the 
biological validation of our framework, which indicates the retrieval of proper 
information. 
5.1 Reduction of Systemic Bias by Distributed Model 
As discussed in section 2.3, systemic bias occurs due to different sized and 
irrelevant entities in the global model. It causes stronger association for small sized 
entities and weaker association for large sized entities.  The distributed model used in this 
study has significantly improved the performance by eliminating systemic bias from the 
model. To analyze the systemic bias effect, we chose 5 small sized entities: 
Blepharoplasty, Atherectomy Coronary, Comunication Aids for Disabled, Amplifiers 
Electrionic, Body Surface Potential Mapping, and 5 large sized entities: Chelating 
Agents, Proline, Cysteine, Lactic Acid, and Vitamin A. We performed cosine similarity 
between these entities and all words in our corpus. We considered global model and 
different clustered distributed model to perform this analysis. In case of small sized 
entities, the average of top 10 ranked scores found to be 0.9157 by global model, 0.8681 
by 2-cluster distributed model and 0.8630 by 3-cluster distributed model. And, in case of 
large sized entities, the average of the top 10 ranked scores found to be 0.8265 by global 
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model, 0.8224 by 2-cluster distributed model and 0.8825 by 3-cluster distributed model. 
The result is illustrated in Figure 5.1. The figure clearly shows that there exists systemic 
bias in global model, which is partially eliminated in 2-cluster distributed model and is 





Figure 5.1. Systemic bias issue in different models. The global model observes a 
significant different between similarity score for small and large sized entities. The bias is 





Distributed model observes to have better utilization of second order co-
occurrences of latent semantic analysis. There are some indirect associations between 
pharmacological entities, which were retrieved through distributed model. Global model 
occasionally fails to retrieve indirect associations due to inability to address local 
concepts. For instance, the association between Atherectomy Coronary and Stroke found 
to be -0.0667 in global model, but 0.4428 in 2-cluster distributed model. By surveying 
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biological literature, we found that Atherectomy Coronary is a procedure, which opens 
narrower coronary arteries to increase blood flow. The procedure indirectly increases the 





Figure 5.2. Comparison between cosine and correntropy similarity. Cosine similarity can 





5.2 Impact of Different Similarity Measures 
In this study, we used cosine similarity to measure the relationship between 
pharmacological entities. However, we also explored correntropy similarity as a non-
linear similarity measure, which may work well for small datasets, but fails to distinguish 
stronger and weaker associations in a sufficiently large datasets. We performed Stroke as 
a query and obtained 0.5177 and 0.0651 as average similarity score of first 10 ranked 
entities using cosine and correntropy, respectively. Furthermore, the entities ranked 
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between 51st and 60th observed average score of 0.2475 for cosine and 0.0389 for 
correntropy, which infers significant difference between higher and lower ranked entities 
using cosine, but not in the case of correntropy. Figure 5.2 illustrates the outcome, which 
clearly shows the poor performance of correntropy similarity in our dataset. 
5.3 Improved Information Retrieval using Multi-gram Dictionary 
The usage of multi-gram dictionary significantly improves the quality of retrieved 
information. There are lots of biological words, which are multi-gram and lose their 
meaning in 1-gram model. For instance, the meaning of Blood Cancer is lost in a 1-gram 
model, which considers Blood and Cancer independently. The quality of retrieved 
information significantly degrades in 1-gram model, when each keyword of a multi-gram 
word has strong independent meaning. However, it is difficult to measure the quality of 
biological information mathematically. Therefore, we performed literature survey to 
justify our claim. We applied some multi-gram keywords in both 1-gram and multi-gram 
model and crosschecked the retrieved information with biological literature. In this 
section, we are going to explain how multi-gram model enhances the quality of retrieved 
information for a query Kidney Failure. We retrieved the top 100 ranked 
pharmacological entities related to Kidney Failure using both 1-gram and multi-gram 
model. By analyzing top 20 ranked entities retrieved from multi-gram model, we found 
Peritoneal Dialysis, and Heart Transplantation not to occur in first 100 entities from 1-
gram model. However, Peritoneal Dialysis is a treatment method for advanced and 
permanent Kidney Failure. And, Heart Transplantation is a surgical procedure, which 
may cause Kidney Failure as a side effect. Therefore, multi-gram model retrieved some 
information, which was not detected by 1-gram model.  
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5.4 Biological Validation of PharmNet 
Along with improved method and performance, the retrieved information and 
network should be biologically meaningful. The goal of a biological information retrieval 
framework is to return useful and meaningful information to the user. In this section, we 
performed some case studies to make sure that we are getting accurate information. For 
this purpose, we manually analyzed some query results and validated the information 
from the literature. Furthermore, we built a network and validated the relationship 
between pharmacological entities in the similar way. 
To analyze query results, we performed Stroke as a query and PharmNet returned 
Fibrinolytic Agents, Thrombolytic Therapy, Fibrin Modulating Agents, Reperfusion and 
Tissue Plasminogen Activator as five topmost ranked pharmacological entities. We 
performed literature survey on these entities to validate their biological relationships. 
Fibrinolytic Agents is a class of drug used for treatment of Stroke [46]. This drug 
achieves reperfusion by converting plasminogen to plasmin, cleaving fibrin, dissolving 
clot and finally restoring the blood flow to ischemic tissues [47]. Thrombolytic Therapy is 
the class of treatment which dissolves blood clots and attempt to recover the damage 
caused by the blockage of the blood vessel [48]. It serves as a therapeutic technique for 
Stroke. Fibrin Modulating Agents are responsible for the chemical actions for affecting 
the function of fibrin, which is basically a protein causing clotting of blood. Therefore, 
these agents indirectly cause blood coagulation, serving as one of the reasons for Stroke. 
Reperfusion is the restoration of blood flow to an organ or tissue. It is considered as the 
most beneficial therapy to Stroke, which is caused by the malfunction of blood supply to 
the brain [49]. Therapeutic reperfusion is found to be an emergency treatment with a 
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remarkable power for the patients with acute brain ischemia and is applicable within 3 
hour time window [49]. Tissue Plasminogen Activator is a protein, which is responsible 
for dissolving blood clots [50]. It serves as a drug to treat embolic or thrombotic stroke. It 
catalyzes the conversion of plagminogen into plasmin causing the degradation of fibrin. 
Eventually, we found the retrieved pharmacological entities to be strongly linked with 





Figure 5.3. Network visualization between Stroke and Clot using PharmNet. The 
relationship between Stroke and Clot is displayed through the related pharmacological 




We also performed validation of pharmacological network obtained from 
PharmNet. We built network to explore relationship between Stroke and Clot. Figure 5.3 
illustrates the network diagram from PharmNet involving the query and related 
pharmacological entities. It shows the relationship between Stroke and Clot through 
Tissue Plasminogen Activator, Fibrinolytic Agents, Fibrin Modulating Agents, Heparin 
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Low-Molecular Weight, Thrombolytic Therapy, Urokinase-Type Plasminogen Activator, 
and Embolic Protection Devices. In general, Stroke is caused the coagulation of blood 
Clot, and the therapeutic technique for this disease lies in dissolution of Clot. However, 
Tissue Plasminogen Activator [50] is a protein which dissolves Clot in blood vessels and 
acts as a drug for Stroke. Fibrinolytic Agents [47] convert plasminogen to fibrinolysin, 
which eventually catalyses the dissolution of Clot. Fibrin Modulating Agents cause the 
possibility of Stroke by catalyzing the production of Clot in blood. Heparin Low-
Molecular Weight is the therapeutic technique of Stroke that inhibits the coagulation of 
blood Clot. Thrombolytic Therapy is a treatment used for dissolving the Clot. Urokinase-
Type Plasminogen Activator is a proteolytic enzyme that converts plasminogen into 
fibrinolysin affecting dissolution of Clot. Embolic Protection Devices provide mechanical 
protection of distal end organ from blood Clot. Therefore, the case study certainly 

















In this study, we presented a literature mining framework for pharmacological 
information retrieval and network visualization. We addressed the scalability issue 
through the construction of distributed model. We also addressed systemic bias issue 
through a systematic way of identification of pharmacological entities and model 
clustering. We showed how the structure of biological information can be utilized for 
efficient model clustering. However, we did not consider fuzzy clustering in this study, 
which may be more meaningful. There are biological concepts, which may belong to 
several clusters. For instance, 3’5’-Cyclic-AMP Phosphodiesterases belongs to Enzyme 
and Amino Acid class at the same time. Hard clustering fails to address the dual meaning 
of a keyword.  
However, we considered a multi-gram model in our framework, which improves 
the quality of retrieved information. We used the tested parameters to build the web-
based literature mining tool PharmNet. We validated the retrieved information and 
pharmacological network obtained from PharmNet by manual examination of  the 
biological literature. One of the limitations of PharmNet is its inability to draw 
relationships between intermediate pharmacological entities. In this framework, we 
considered only chemical compounds, drugs, biological factors, diagnosis, procedure, etc. 
as entities to perform analysis. However, this framework is flexible to append new 
entities, such as gene, protein to build network using heterogeneous components.  
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Increased volume of information, building hypothesis, and translating of discoveries into 
clinical practice are major challenges in pharmacology. We addressed the first issue by 
performing large scale literature processing and mining, and second issue by network 
visualization of pharmacological entities. This study serves as a baseline to integrate 
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List of Pharmacological Entities 
 


























6-Ketoprostaglandin F1 alpha 
6-Mercaptopurine 



















Ischemic Preconditioning, Myocardial 











































Actinoid Series Elements 






Acute Toxicity Tests 
ADAM Proteins 





















































Lens Implantation, Intraocular 
Lenses, Intraocular 




Leukocyte Migration-Inhibitory Factors 





Life Support Care 
Life Tables 
Light Coagulation 













Air Pollutants, Occupational 
































Amine Oxidase (Copper-Containing) 
Amino Acid Chloromethyl Ketones 
Amino Acid Transport Systems, Acidic 






















Liver Function Tests 













Macrophage Colony-Stimulating Factor 
Macrophage Inflammatory Proteins 























































Angiogenesis Modulating Agents 
Angiography, Digital Subtraction 























Medical History Taking 
Medical Record Linkage 
















Mesenchymal Stem Cell Transplantation 
Meta-Analysis as Topic 
Metabolic Clearance Rate 









Angiotensin Receptor Antagonists 
Angiotensin-Converting Enzyme Inhibitors 
Angiotensinogen 
Anilino Naphthalenesulfonates 
Animal Use Alternatives 














Antidepressive Agents, Second-Generation 






















































Microscopy, Electron, Transmission 










Middle Ear Ventilation 
Mifepristone 









Antigens, Differentiation, B-Lymphocyte 






Antigens, Tumor-Associated, Carbohydrate 
Antigens, Viral, Tumor 
Anti-HIV Agents 
Anti-Infective Agents, Local 





Antimicrobial Cationic Peptides 
Antimutagenic Agents 
Antimycin A 
Antineoplastic Agents, Alkylating 
Antineoplastic Agents, Hormonal 
Antineoplastic Agents, Phytogenic 
Antiporters 
Antiprotozoal Agents 


























Molecular Diagnostic Techniques 
Molecular Dynamics Simulation 
Molecular Epidemiology 





Monoamine Oxidase Inhibitors 
Monobactams 




















Myeloid Differentiation Factor 88 
Myeloma Proteins 
Myogenic Regulatory Factors 
Myoglobin 















Area Under Curve 
Arginase 





























































Nerve Growth Factor 










Neurotransmitter Uptake Inhibitors 
Neurotrophin 3 
Neutralization Tests 
NF-E2-Related Factor 2 























































Nitric Oxide Donors 
Nitric Oxide Synthase Type I 
Nitric Oxide Synthase Type II 






















Nuclear Magnetic Resonance, 
Biomolecular 
Nuclear Matrix-Associated Proteins 
Nuclear Reactors 
Nuclear Receptor Coactivators 
Nuclear Transfer Techniques 
Nuclease Protection Assays 
Nucleic Acid Denaturation 
Nucleic Acid Heteroduplexes 
Nucleic Acid Synthesis Inhibitors 
Nucleocytoplasmic Transport Proteins 































Blood Coagulation Tests 
Blood Component Transfusion 
Blood Glucose Self-Monitoring 
Blood Preservation 
Blood Pressure Determination 
Blood Protein Electrophoresis 
Blood Sedimentation 
Blood Specimen Collection 
Blood Substitutes 
Blood Transfusion, Autologous 
Blood Urea Nitrogen 
Blood Vessel Prosthesis 
Blood Vessel Prosthesis Implantation 
Body Height 
Body Modification, Non-Therapeutic 
Body Surface Potential Mapping 
Bone Cements 
Bone Lengthening 


































Organ Culture Techniques 
Organ Preservation 









Orphan Nuclear Receptors 

















Brain Tissue Transplantation 
Brain Waves 




























Calcitonin Gene-Related Peptide 
Calcium Carbonate 
Calcium Channel Agonists 
Calcium Channels, L-Type 













Oxidoreductases Acting on CH-CH Group 
Donors 


























Parasite Egg Count 











































































Peptide Elongation Factors 
Peptide Initiation Factors 
Peptide Library 
Peptide Mapping 

























CARD Signaling Adaptor Proteins 
Cardiac Pacing, Artificial 
































CCN Intercellular Signaling Proteins 
CD40 Ligand 
CDC2 Protein Kinase 


























































Cerebrospinal Fluid Proteins 

















Chemotactic Factors, Eosinophil 
Chemotherapy, Adjuvant 









































Photosynthetic Reaction Center Complex 
Proteins 
Photosystem I Protein Complex 



















Pit and Fissure Sealants 
Pituitary Adenylate Cyclase-Activating 
Polypeptide 
Plant Exudates 














Chorionic Gonadotropin, beta Subunit, 
Human 





Chromatography, Ion Exchange 
Chromatography, Paper 






















Clinical Enzyme Tests 
Clinical Trials, Phase I as Topic 
Clinical Trials, Phase II as Topic 





Plasminogen Activator Inhibitor 1 
Plasminogen Inactivators 
Plasticizers 
Platelet Activating Factor 
Platelet Aggregation Inhibitors 
Platelet Count 
Platelet Factor 4 
Platelet Function Tests 
























































Colony-Forming Units Assay 
Colony-Stimulating Factors, Recombinant 
Color Perception Tests 
Colposcopy 
Combinatorial Chemistry Techniques 
Communication Aids for Disabled 
Comparative Genomic Hybridization 
Complement Activating Enzymes 
Complement C1 




Complement Factor B 
Complement Factor H 
Complement Fixation Tests 
Complement Inactivator Proteins 
Complement Membrane Attack Complex 

















Potassium Channel Blockers 
Potassium Channels, Calcium-Activated 
Potassium Channels, Inwardly Rectifying 





































Contraceptive Devices, Female 
Contraceptive Devices, Male 
Contrast Sensitivity 
Copper Sulfate 
Cord Blood Stem Cell Transplantation 
Corneal Surgery, Laser 
Corneal Topography 
Corneal Transplantation 




















Culture Media, Conditioned 



































Proteasome Endopeptidase Complex 
Protective Clothing 




Protein Interaction Mapping 
Protein Kinase Inhibitors 
Protein S 
Protein Sorting Signals 
Protein Subunits 
Protein Synthesis Inhibitors 
Protein Tyrosine Phosphatase, Non-
Receptor Type 11 
Protein Tyrosine Phosphatase, Non-






Proto-Oncogene Proteins c-abl 
Proto-Oncogene Proteins c-akt 
Proto-Oncogene Proteins c-bcl-2 
Proto-Oncogene Proteins c-bcr 
Proto-Oncogene Proteins c-fos 
Proto-Oncogene Proteins c-jun 













Cysteine Proteinase Inhibitors 







Cytochrome b Group 
Cytochrome c Group 
Cytokine Receptor gp130 
Cytopathogenic Effect, Viral 
Cytosine 
Cytosine Nucleotides 









Death Domain Receptor Signaling Adaptor 
Proteins 
Decanoic Acids 










Proto-Oncogene Proteins c-mdm2 
Proto-Oncogene Proteins c-met 
Proto-Oncogene Proteins c-myc 
Proto-Oncogene Proteins c-ret 








Pulmonary Gas Exchange 





























rab GTP-Binding Proteins 
Rabies Vaccines 




Dental Care for Aged 
Dental Care for Children 
Dental Care for Chronically Ill 
Dental Care for Disabled 
Dental Casting Technique 
Dental Cavity Preparation 
Dental Enamel Proteins 
Dental Etching 
Dental Health Surveys 
Dental Implantation 
Dental Implantation, Endosseous 
Dental Implants 
Dental Impression Materials 
Dental Impression Technique 
Dental Instruments 
Dental Marginal Adaptation 
Dental Occlusion, Centric 
Dental Plaque Index 
Dental Porcelain 
Dental Prophylaxis 
Dental Prosthesis Design 
Dental Prosthesis Retention 
Dental Prosthesis, Implant-Supported 
Dental Restoration Failure 




















Diabetes Mellitus, Experimental 
























Random Amplified Polymorphic DNA 
Technique 
Range of Motion, Articular 
RANK Ligand 
rap GTP-Binding Proteins 
ras Proteins 
Reagent Kits, Diagnostic 
Reagent Strips 
Rec A Recombinases 
Receptor Activator of Nuclear Factor-
kappa B 
Receptor, Bradykinin B2 
Receptor, Epidermal Growth Factor 
Receptor, erbB-2 





Receptor-Like Protein Tyrosine 
Phosphatases 
Receptor-Like Protein Tyrosine 














Differential Thermal Analysis 

































DNA Modification Methylases 
Receptors, Adrenergic, alpha 
Receptors, Adrenergic, beta 
Receptors, Androgen 
Receptors, Angiotensin 
Receptors, Antigen, B-Cell 
Receptors, Antigen, T-Cell, alpha-beta 
Receptors, Antigen, T-Cell, gamma-delta 










































DNA Polymerase I 
DNA Polymerase II 
DNA Polymerase III 
DNA Repair Enzymes 
DNA Topoisomerases 
DNA Transposable Elements 







































Receptors, Lymphocyte Homing 
Receptors, Metabotropic Glutamate 
Receptors, Mineralocorticoid 
Receptors, Muscarinic 
Receptors, Nerve Growth Factor 
Receptors, Neuropeptide Y 
Receptors, Nicotinic 
Receptors, NK Cell Lectin-Like 
Receptors, Notch 
Receptors, Oncostatin M, Type II 
Receptors, Opioid 
Receptors, OSM-LIF 
Receptors, Pancreatic Hormone 
Receptors, Pattern Recognition 
Receptors, Pituitary Hormone-Regulating 
Hormone 




Receptors, Purinergic P2X 
Receptors, Retinoic Acid 







Receptors, Thyroid Hormone 
Receptors, Thyrotropin 
Receptors, Transforming Growth Factor 
beta 
Receptors, Tumor Necrosis Factor, Type I 
Receptors, Tumor Necrosis Factor, Type II 
Receptors, Vascular Endothelial Growth 
Factor 
Receptors, Vasoactive Intestinal Peptide 
Receptors, Vasopressin 




























Electron Probe Microanalysis 
Electron Spin Resonance Spectroscopy 
Electron Transport Complex I 
Electron Transport Complex III 
Electron Transport Complex IV 
Electron-Transferring Flavoproteins 
Electrophoresis, Agar Gel 
Electrophoresis, Capillary 
Electrophoresis, Gel, Pulsed-Field 
Electrophoresis, Gel, Two-Dimensional 
Electrophoresis, Paper 










Endosomal Sorting Complexes Required 
for Transport 
Endosonography 






Rehabilitation of Hearing Impaired 
















Retinoblastoma Binding Proteins 
Retinoblastoma Protein 
Retroviridae Proteins, Oncogenic 
Reverse Transcriptase Inhibitors 
Rheumatoid Factor 
Rhinoplasty 




Ribosome Inactivating Proteins 




Riot Control Agents, Chemical 
Risperidone 
Ritonavir 






















Epstein-Barr Virus Nuclear Antigens 














Estrogen Receptor alpha 
Estrogen Receptor beta 
Estrogen Receptor Modulators 
Estrogenic Steroids, Alkylated 











Exchange Transfusion, Whole Blood 
Excitatory Amino Acid Agents 
Exercise Movement Techniques 
Exercise Therapy 
RNA, Ribosomal, 18S 
RNA, Ribosomal, 23S 
RNA, Ribosomal, 28S 
RNA, Ribosomal, 5S 
RNA, Small Interfering 
RNA, Small Nuclear 
RNA, Transfer 
RNA, Transfer, Amino Acyl 
RNA-Directed DNA Polymerase 
ROC Curve 
Root Canal Filling Materials 
Root Canal Preparation 





















Scavenger Receptors, Class B 
Schiff Bases 

















Extracellular Signal-Regulated MAP 
Kinases 
Extracorporeal Membrane Oxygenation 
Extraction, Obstetrical 
Eye Enucleation 










False Negative Reactions 
False Positive Reactions 
Famotidine 
Fanconi Anemia Complementation Group 
Proteins 
Farnesyltranstransferase 
Fas Ligand Protein 
Fasting 
Fats, Unsaturated 
Fatty Acid Desaturases 
Fatty Acid Synthetase Complex 
Fatty Acids, Nonesterified 
Fatty Acids, Omega-3 


























Serine Proteinase Inhibitors 
Serotonin Antagonists 
Serotonin Receptor Agonists 
Serotonin Uptake Inhibitors 
Serotyping 
Serum Albumin, Bovine 
Serum Amyloid A Protein 
Sewage 
Sex Attractants 
Sex Determination Analysis 
Sex Hormone-Binding Globulin 


























Fetal Tissue Transplantation 
Fibrillar Collagens 
Fibrin 


























Fluorescence Resonance Energy Transfer 
Fluorescent Antibody Technique, Direct 









Focal Adhesion Kinase 1 
Focus Groups 
Follicle Stimulating Hormone 
Food Additives 
Forced Expiratory Flow Rates 








Sodium Channel Blockers 
Sodium Channels 
Sodium Chloride Symporter Inhibitors 


















Spectrometry, Mass, Electrospray 
Ionization 
Spectrometry, Mass, Fast Atom 
Bombardment 
Spectrometry, Mass, Matrix-Assisted Laser 
Desorption-Ionization 
Spectrometry, X-Ray Emission 
Spectrophotometry, Atomic 
Spectroscopy, Fourier Transform Infrared 
Spectrum Analysis, Raman 















Foster Home Care 
Fractals 
Fragile X Mental Retardation Protein 






















Gastric Acidity Determination 
Gastric Bypass 























Staphylococcal Protein A 
Startle Reaction 




































Gene Products, env 
Gene Products, gag 
Gene Products, nef 
Gene Products, tat 
Gene Products, tax 
Gene Targeting 
Genetic Association Studies 
Genetic Complementation Test 
Genetic Testing 
Genome-Wide Association Study 
Gentamicins 
Gentian Violet 
Glasgow Coma Scale 
Glial Cell Line-Derived Neurotrophic 
Factors 
Glial Fibrillary Acidic Protein 
Glomerular Filtration Rate 
Gluconates 
Glucose Clamp Technique 
Glucose Oxidase 

















Glycine Decarboxylase Complex 
Glycogen 
Glycolates 
























Suppressor of Cytokine Signaling Proteins 
















Tacrolimus Binding Proteins 
Tamoxifen 







Technetium Tc 99m Aggregated Albumin 













GRB2 Adaptor Protein 
Growth Differentiation Factors 
Growth Hormone-Releasing Hormone 
Growth Inhibitors 









Guided Tissue Regeneration 










Head Protective Devices 
Health Care Surveys 
Hearing Aids 
Heart Arrest, Induced 
Heart Auscultation 
Heart Bypass, Right 
Heart Transplantation 
Heart Valve Prosthesis 
Heart Valve Prosthesis Implantation 
Heart, Artificial 
Heart-Assist Devices 
Heat-Shock Proteins, Small 






















































Hematopoietic Stem Cell Mobilization 
Hematopoietic Stem Cell Transplantation 
Hematoporphyrins 


























High Mobility Group Proteins 
High-Frequency Ventilation 






























Tissue and Organ Harvesting 
Tissue Array Analysis 





Tissue Inhibitor of Metalloproteinases 






























Hormone Replacement Therapy 
Horseradish Peroxidase 
Hospital Mortality 
HSP40 Heat-Shock Proteins 
HSP70 Heat-Shock Proteins 
HSP90 Heat-Shock Proteins 


































Transcranial Magnetic Stimulation 
Transcription Factor AP-1 
Transcription Factor RelA 
Transcription Factors, General 





Transforming Growth Factor alpha 
Transforming Growth Factor beta1 






Transportation of Patients 
Transposases 


































































Infusion Pumps, Implantable 
Infusions, Intra-Arterial 
Inhibins 






Tumor Necrosis Factor Decoy Receptors 
Tumor Necrosis Factor Receptor-
Associated Peptides and Proteins 
Tumor Stem Cell Assay 
Tunicamycin 









Ultrasonography, Doppler, Pulsed 















Urinary Reservoirs, Continent 
Urography 



















Injury Severity Score 
Inlays 
Inosine 






Insulin Infusion Systems 
Insulin Receptor Substrate Proteins 
Insulin-Like Growth Factor Binding 
Proteins 
Insulin-Like Growth Factor I 
Insulin-Like Growth Factor II 
Integrin alpha Chains 
Integrin alphaXbeta2 
Integrin beta Chains 
Intercalating Agents 
Intercellular Adhesion Molecule-1 
Interferon Inducers 
Interferon Regulatory Factor-1 
Interferon Regulatory Factors 



















Vascular Cell Adhesion Molecule-1 
Vascular Endothelial Growth Factor A 
Vasectomy 







Vesicular Neurotransmitter Transport 
Proteins 






Viral Fusion Proteins 
Viral Hepatitis Vaccines 
Viral Load 
Viral Matrix Proteins 
Viral Nonstructural Proteins 
Virulence Factors, Bordetella 
Virus Cultivation 
Vision Screening 




Von Hippel-Lindau Tumor Suppressor 
Protein 
von Willebrand Factor 
Water Pollutants, Radioactive 































Xenograft Model Antitumor Assays 
Xenon Isotopes 
X-Ray Diffraction 
Xylans 
Xylazine 
Xylitol 
Xylosidases 
Yohimbine 
Yttrium Isotopes 
Zearalenone 
Zinc Oxide 
Zinc Sulfate 
 
